Severe oral erosive lichenoid reaction to pembrolizumab therapy

Indraneel Bhattacharyya; Hardeep Chehal; Cesar Migliorati

doi:10.1016/j.oooo.2020.06.014

Severe oral erosive lichenoid reaction to pembrolizumab therapy

Indraneel Bhattacharyya, Hardeep Chehal, Cesar Migliorati

Department of Diagnostic Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

New advances in cancer immunotherapy have been flooding the market at a rapid rate. Pembrolizumab (Keytruda), a programmed cell death protein 1 inhibitor, introduced in 2014, has been used to treat several cancers. Immune-related adverse events associated with pembrolizumab and other immune checkpoint inhibitors are now well-described complications. We describe the case of a 65-year old female with severe oral lichenoid lesions occurring after treatment with pembrolizumab for bladder cancer. To the best of our knowledge, this is the first report of a biopsy-proven oral erosive lichenoid reaction confirmed through direct immunofluorescence.

Original language	English (US)
Pages (from-to)	e301-e307
Journal	Oral surgery, oral medicine, oral pathology and oral radiology
Volume	130
Issue number	5
DOIs	https://doi.org/10.1016/j.oooo.2020.06.014
State	Published - Nov 2020

All Science Journal Classification (ASJC) codes

Surgery
Oral Surgery
Pathology and Forensic Medicine
Dentistry (miscellaneous)
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.oooo.2020.06.014

Fingerprint Dive into the research topics of 'Severe oral erosive lichenoid reaction to pembrolizumab therapy'. Together they form a unique fingerprint.

Cite this

@article{9bc5483bca6e4e4a84817fcb4602bae8,

title = "Severe oral erosive lichenoid reaction to pembrolizumab therapy",

abstract = "New advances in cancer immunotherapy have been flooding the market at a rapid rate. Pembrolizumab (Keytruda), a programmed cell death protein 1 inhibitor, introduced in 2014, has been used to treat several cancers. Immune-related adverse events associated with pembrolizumab and other immune checkpoint inhibitors are now well-described complications. We describe the case of a 65-year old female with severe oral lichenoid lesions occurring after treatment with pembrolizumab for bladder cancer. To the best of our knowledge, this is the first report of a biopsy-proven oral erosive lichenoid reaction confirmed through direct immunofluorescence.",

author = "Indraneel Bhattacharyya and Hardeep Chehal and Cesar Migliorati",

year = "2020",

month = nov,

doi = "10.1016/j.oooo.2020.06.014",

language = "English (US)",

volume = "130",

pages = "e301--e307",

journal = "Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology",

issn = "2212-4403",

publisher = "Elsevier USA",

number = "5",

}

TY - JOUR

T1 - Severe oral erosive lichenoid reaction to pembrolizumab therapy

AU - Bhattacharyya, Indraneel

AU - Chehal, Hardeep

AU - Migliorati, Cesar

PY - 2020/11

Y1 - 2020/11

N2 - New advances in cancer immunotherapy have been flooding the market at a rapid rate. Pembrolizumab (Keytruda), a programmed cell death protein 1 inhibitor, introduced in 2014, has been used to treat several cancers. Immune-related adverse events associated with pembrolizumab and other immune checkpoint inhibitors are now well-described complications. We describe the case of a 65-year old female with severe oral lichenoid lesions occurring after treatment with pembrolizumab for bladder cancer. To the best of our knowledge, this is the first report of a biopsy-proven oral erosive lichenoid reaction confirmed through direct immunofluorescence.

AB - New advances in cancer immunotherapy have been flooding the market at a rapid rate. Pembrolizumab (Keytruda), a programmed cell death protein 1 inhibitor, introduced in 2014, has been used to treat several cancers. Immune-related adverse events associated with pembrolizumab and other immune checkpoint inhibitors are now well-described complications. We describe the case of a 65-year old female with severe oral lichenoid lesions occurring after treatment with pembrolizumab for bladder cancer. To the best of our knowledge, this is the first report of a biopsy-proven oral erosive lichenoid reaction confirmed through direct immunofluorescence.

UR - http://www.scopus.com/inward/record.url?scp=85087710569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85087710569&partnerID=8YFLogxK

U2 - 10.1016/j.oooo.2020.06.014

DO - 10.1016/j.oooo.2020.06.014

M3 - Article

C2 - 32654932

AN - SCOPUS:85087710569

VL - 130

SP - e301-e307

JO - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

JF - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

SN - 2212-4403

IS - 5

ER -